News|Articles|November 20, 2026

Rethinking Idiopathic Intracranial Hypertension as a Disorder of Arterial Hemodynamics

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • Venous sinus stenting may increase cerebral arterial inflow, implying venous congestion can depress forward arterial perfusion and potentially contribute to IIH symptomatology beyond raised intracranial pressure.
  • Prior literature emphasizes symptomatic improvement and headache control in medication-refractory IIH, while arterial-side physiology and mechanistic correlates remain underexplored compared with venous metrics.
SHOW MORE

Chris Favilla, MD, stroke neurologist at the University of Pennsylvania, discusses findings that cerebral venous sinus stenting improves arterial hemodynamics in patients with idiopathic intracranial hypertension (IIH) and what they mean for understanding the disease.

The 2026 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, held in Las Vegas, Nevada, marked the society’s 20th annual gathering under the chair’s theme “SVIN 2026: All In!” The meeting brought together researchers, practitioners, and industry leaders in vascular and interventional neurology, with keynote lectures, interactive workshops, and poster presentations centered on advances in stroke and neurointervention.

Among the presentations was a study examining how cerebral venous sinus stenting affects arterial hemodynamics in patients with idiopathic intracranial hypertension (IIH). Stenting is generally viewed as a treatment for venous outflow obstruction, but early observations suggest it may also increase blood flow to the brain, raising the possibility that chronic, low-grade hypoperfusion contributes to symptoms such as headache, brain fog, and subtle cognitive complaints.

During the meeting, NeurologyLive sat down with Chris Favilla, MD, a stroke neurologist at the University of Pennsylvania, who presented the work, to discuss the findings and their implications. Favilla answered questions on the rationale for studying the arterial side of venous disease, how the results build on existing evidence, and what future research is needed to link hemodynamic changes to clinical outcomes. He also covered the knowledge gaps that persist in caring for patients with IIH, the role of guidelines at this stage, and what stands out to him about the meeting.

NeurologyLive: For those who may not have had a chance to sit in on your presentation at SVIN, can you give some background on the talk and why this topic was of interest to you?

Chris Favilla, MD: In this study, we were exploring the arterial side of venous sinus disease in patients with intracranial hypertension, or pseudotumor cerebri. The interest came because when you intervene on venous pathology in these patients, it is predominantly thought of as a venous disease. There is some venous outflow obstruction, and intervening with a stent is meant to address that specific pathophysiology. But we have made some early observations suggesting there are surprising arterial consequences to that intervention. You think that by putting in a stent you are going to increase drainage, which you do, ideally. But the congestive process has implications for arterial blood flow upstream, essentially reducing blood flow.

What we are getting at is twofold. First, we are making observations implying that the intervention has arterial benefits and increases blood flow to the brain. That is particularly interesting because it may have implications for the pathophysiology of the disease. We don’t think of this as a blood flow problem. Maybe there is a drainage problem, but the fact that blood flow goes up in so many of these patients when we restore venous drainage implies that they may be living with a chronic hypoperfusion state. It isn’t profound hypoperfusion or ischemic conditions, but there may be enough hypoperfusion to contribute to some of the symptoms.

A lot of us struggle with this disease state. There is some subjectivity to the symptoms, such as headaches, brain fog, and subtle cognitive complaints. I think we are only scratching the surface right now, but there is a possible scenario in which impaired arterial hemodynamics are driving a piece of that disease.

What has been done previously, and how does your work add to the evidence?

The preponderance of the evidence in this space is in the venous realm, looking at venous intervention to improve venous outflow. Other groups have demonstrated that the intervention is efficacious in many medication-refractory patients, with improvement in symptom control and better headache control. So, the evidence for venous interventions surrounds clinical efficacy but does not get at the arterial side.

The closest I have seen to this is a couple of groups that have done some nice work looking at glymphatic drainage, which is certainly a hot topic in a number of neurological diseases. It is hard to study, and hard to know for sure that is what we are imaging, but some groups have demonstrated early signs of improved drainage when you stent a vein in this patient population. Still, they are not directly looking at the arterial side. If you think about venous disease through an analogous disease state, take venous sinus thrombosis. Those patients can have ischemic strokes because there is so much congestion that it slows forward flow through the circuit.

So, there is clearly precedent for the idea that venous obstruction can have arterial consequences. I think there just hasn’t been a lot of attention paid to it. The intervention we are talking about is still in its infancy, though it has evolved a lot in the last few years, so we are looking at an almost untapped opportunity to study this more deeply.

What are the next steps for your research, and what is your call to action for the clinical community?

There is a lot to do. The observations we have made are preliminary, and we need to associate the arterial hemodynamic changes with clinical outcomes that matter. Even though I am a blood flow guy, seeing changes in arterial blood flow is kind of meaningless if there is no meaningful clinical outcome associated with it.

We also need to use these data to understand the pathophysiology. If we can use hemodynamic data not just to understand the treatment but to understand the core disease, I think we can figure out how to refine this treatment better. We can start to pick the patients who are going to benefit the most, which I think right now is really challenging in this disease population.

What more can we do as a clinical community to understand IIH, and what misconceptions or knowledge gaps are most prevalent when talking about these patients?

One of the challenges for many clinicians, myself included, is the seeming subjectivity around the symptoms. Things like brain fog and certain cognitive complaints, and even headaches, are hard to quantify. We can use scales to quantify the severity and frequency of headaches, but we worry when symptoms are not things we can measure or see on a scan, and that makes us uncomfortable when we think about how to treat them. So, we need to be clear about how we are quantifying these symptoms. We need to either accept the symptoms at face value or come up with clear, objective ways of studying and understanding them. Without that, it is hard to understand the disease, and therefore hard to understand the treatment effect.

What role do guidelines play for this type of disorder, and are there areas where we could improve?

Our venous interventions for IIH are still at a relatively early stage, so I think it is premature for guidelines to be practice changing in this space. There could be a role for guidelines that make very inclusive, opportunistic comments about the possible value of these interventions. But we still need to learn so much more about patient selection and how we deploy this intervention. I think more forceful guidelines would hamstring the intervention at a time when it doesn’t need to be hamstrung.

What excites you most about SVIN 2026, and what grabs your attention at this type of meeting?

I love being at a meeting like this, especially as a noninterventionist. I am a stroke neurologist, and I love this meeting because the interventional world is evolving so rapidly that if you just keep your eyes and ears open, there are opportunities to see where the field is going and find new space to explore, study, and learn.

Transcript edited for clarity. For more SVIN 2026 coverage, click here.


Related to this article